Johnson & Johnson (NYSE:JNJ)’s share price traded up 1.3% on Tuesday . The company traded as high as $123.23 and last traded at $122.90, with a volume of 4,776,053 shares. The stock had previously closed at $121.29.

Several research firms have commented on JNJ. Jefferies Group reiterated a “hold” rating and set a $109.00 price objective (up from $108.00) on shares of Johnson & Johnson in a research note on Tuesday, June 14th. Goldman Sachs Group Inc. set a $121.00 price objective on Johnson & Johnson and gave the stock a “neutral” rating in a research note on Monday, June 13th. Wells Fargo & Co. reiterated a “buy” rating on shares of Johnson & Johnson in a research report on Monday, June 6th. Vetr cut Johnson & Johnson from a “hold” rating to a “sell” rating and set a $109.97 price target on the stock. in a research note on Monday, June 6th. Finally, BTIG Research restated a “neutral” rating on shares of Johnson & Johnson in a research note on Friday, June 3rd. Two analysts have rated the stock with a sell rating, twelve have issued a hold rating and nine have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $112.36.

The stock has a market cap of $337.34 billion and a P/E ratio of 22.35. The stock has a 50-day moving average of $116.04 and a 200 day moving average of $108.67.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, April 19th. The company reported $1.68 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.65 by $0.03. The company had revenue of $17.50 billion for the quarter, compared to analysts’ expectations of $17.50 billion. The firm’s quarterly revenue was up .6% on a year-over-year basis. During the same period in the prior year, the firm earned $1.56 earnings per share. On average, equities research analysts forecast that Johnson & Johnson will post $6.61 EPS for the current year.

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 7th. Stockholders of record on Tuesday, May 24th were paid a dividend of $0.80 per share. The ex-dividend date of this dividend was Friday, May 20th. This is an increase from Johnson & Johnson’s previous quarterly dividend of $0.75. This represents a $3.20 annualized dividend and a dividend yield of 2.61%.

In other news, VP Gary J. Pruden sold 9,735 shares of the business’s stock in a transaction on Tuesday, June 7th. The shares were sold at an average price of $116.03, for a total transaction of $1,129,552.05. Following the completion of the sale, the vice president now directly owns 43,630 shares of the company’s stock, valued at approximately $5,062,388.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CAO Ronald A. Kapusta sold 3,000 shares of the business’s stock in a transaction on Tuesday, June 7th. The shares were sold at an average price of $115.79, for a total transaction of $347,370.00. Following the sale, the chief accounting officer now directly owns 28,725 shares of the company’s stock, valued at $3,326,067.75. The disclosure for this sale can be found here.

Several institutional investors have bought and sold shares of the stock. Heritage Wealth Advisors raised its position in Johnson & Johnson by 3.3% in the fourth quarter. Heritage Wealth Advisors now owns 9,944 shares of the company’s stock valued at $1,021,000 after buying an additional 317 shares during the last quarter. S. R. Schill & Associates raised its position in Johnson & Johnson by 122.7% in the fourth quarter. S. R. Schill & Associates now owns 11,110 shares of the company’s stock valued at $1,141,000 after buying an additional 6,121 shares during the last quarter. Lourd Capital LLC raised its position in Johnson & Johnson by 8.3% in the fourth quarter. Lourd Capital LLC now owns 11,115 shares of the company’s stock valued at $1,142,000 after buying an additional 851 shares during the last quarter. Eidelman Virant Capital raised its position in Johnson & Johnson by 11.8% in the fourth quarter. Eidelman Virant Capital now owns 11,623 shares of the company’s stock valued at $1,193,000 after buying an additional 1,231 shares during the last quarter. Finally, Vigilant Capital Management LLC raised its position in Johnson & Johnson by 1.8% in the fourth quarter. Vigilant Capital Management LLC now owns 11,838 shares of the company’s stock valued at $1,216,000 after buying an additional 210 shares during the last quarter.

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.